A Targeted-Covalent Inhibitor of 17β-HSD1 Blocks Two Estrogen-Biosynthesis Pathways: In Vitro (Metabolism) and In Vivo (Xenograft) Studies in T-47D Breast Cancer Models

A Targeted-Covalent Inhibitor of 17β-HSD1 Blocks Two Estrogen-Biosynthesis Pathways: In Vitro (Metabolism) and In Vivo (Xenograft) Studies in T-47D Breast Cancer Models

17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) plays an important role in estrogen-dependent breast tumor growth. In addition to being involved in the production of estradiol (E2), the most potent estrogen in women, 17β-HSD1 is also responsible for the production of 5-androsten-3β,17β-diol (5-di...

Full description

Bibliographic Details
Main Authors: Donald Poirier, Jenny Roy, René Maltais
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
breast cancer
estrogen
hormone
steroid
inhibitor
DHEA
Online Access:https://www.mdpi.com/2072-6694/13/8/1841

Similar Items

Similar Items